Biogen (BIIB) Stock Price, News & Analysis

Company Overview

Biogen Inc. is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders. Biogen has also been active in the Alzheimer's field through collaborations with Eisai, bringing antibodies targeting amyloid pathology to market. In addition, Biogen has worked with partners on treatments for spinal muscular atrophy and other rare diseases, reflecting a mix of proprietary development and co-commercialization arrangements.

Biogen invests heavily in research and development, maintaining clinical-stage programs across a range of neuroscience indications and pursuing both small- and large-molecule approaches. The company operates through a combination of internal discovery, external collaborations, licensing deals and strategic acquisitions to expand its pipeline and commercial reach. Biogen is governed by an executive leadership team and a board of directors responsible for setting corporate strategy and overseeing its global operations.

Key Stats

• Today's Range: $188.30 to $191.17
• 50-Day Range: $172.34 to $196.34
• 52-Week Range: $115.25 to $202.41
• Volume: 741,344 shs
• Average Volume: 1.30 million shs
• Market Capitalization: $28.15 billion
• P/E Ratio: 20.46
• Dividend Yield: N/A
• Price Target: $214.23
• Consensus Rating: Moderate Buy

Biogen Stock Analysis - MarketRank™

Biogen scored higher than 82% of companies evaluated by MarketBeat, and ranked 148th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 13 buy ratings, 13 hold ratings, and 1 sell rating.

Upside Potential

Biogen has a consensus price target of $214.23, representing about 12.9% upside from its current price of $189.69.

Amount of Analyst Coverage

Biogen has been the subject of 25 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.36%

Earnings Growth

Earnings for Biogen are expected to grow by 7.36% in the coming year, from $14.41 to $15.47 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biogen is 20.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.35.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biogen is 20.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.20.

Price to Earnings Growth Ratio

Biogen has a PEG Ratio of 1.62. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Biogen has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.01% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 3.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biogen has recently increased by 15.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biogen does not currently pay a dividend.

Dividend Growth

Biogen does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.79

News Sentiment

Biogen has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 39 news articles for Biogen this week, compared to 16 articles on an average week.

Search Interest

22 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Biogen insiders have sold 90,762.91% more of their company's stock than they have bought. Specifically, they have bought $585.00 in company stock and sold $531,548.00 in company stock.

Percentage Held by Insiders

0.18% of the stock of Biogen is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BIIB Stock Analysis - Frequently Asked Questions

How have BIIB shares performed this year?

Biogen's stock was trading at $175.99 at the beginning of the year. Since then, BIIB shares have increased by 7.8% and is now trading at $189.69.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its earnings results on Wednesday, April, 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen's quarterly revenue was up 1.9% compared to the same quarter last year.
Read the conference call transcript.

Does Biogen have any subsidiaries?

The following companies are subsidiaries of Biogen: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and more.

Who are Biogen's major shareholders?

Biogen's top institutional investors include Pictet Asset Management Holding SA (0.62%), Bank of New York Mellon Corp (0.53%), Candriam S.C.A. (0.26%) and Sumitomo Mitsui Trust Group Inc. (0.24%). Insiders that own company stock include Eric K Rowinsky, Nicole Murphy, Stephen A Sherwin, Stephen A Sherwin, Stephen A Sherwin, Priya Singhal and Rachid Izzar.
View institutional ownership trends.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC).

Company Calendar

• Last Earnings: 4/29/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIIB
• CIK: 875045
• Web: www.biogen.com
• Phone: (617) 679-2000
• Fax: 617-679-2617
• Employees: 7,500
• Year Founded: 1978

Price Target and Rating

• Average Price Target for Biogen: $214.23
• High Price Target: $275.00
• Low Price Target: $150.00
• Potential Upside/Downside: +12.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 28 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.32
• Trailing P/E Ratio: 20.46
• Forward P/E Ratio: 13.23
• P/E Growth: 1.62
• Net Income: $1.29 billion
• Net Margins: 13.81%
• Pretax Margin: 16.33%
• Return on Equity: 12.83%
• Return on Assets: 8.01%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 3.06
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: $9.89 billion
• Price / Sales: 2.85
• Cash Flow: $23.06 per share
• Price / Cash Flow: 8.27
• Book Value: $126.33 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 147,640,000
• Free Float: 147,371,000
• Market Cap: $28.15 billion
• Optionable: Optionable
• Beta: 0.19